ArticleScientific reports2025
A novel tumor microenvironment-related gene signature for prognostic prediction of intrahepatic cholangiocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parthenolide inhibits the progression of intrahepatic cholangiocarcinoma by promoting ferroptosis through inhibiting UBD.Cancer biology & therapy · 2026Article
- GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer.Cancer communications (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICCA) is a highly aggressive bile duct cancer with limited treatment options and poor prognosis. This study aims to develop a gene signature-based model to predict ICCA patient survival. We identified differentially expressed genes (DEGs) from an ICCA mRNA microarray dataset and applied survival, Cox, and LASSO regression analyses to select key genes for constructing the GPSICCA risk score model. The model was then validated in two additional ICCA cohorts, and its relationship with the tumor microenvironment (TME) was analyzed. Additionally, multiplex fluorescent immunohistochemistry (mfIHC) was conducted to examine the expression of key genes in ICCA samples. The expression of COL4A1, GULP1, ITGA6, and STC1 was used to construct the gene set-based prognostic signature for ICCA (GPSICCA) risk score model, and mfIHC confirmed their expression in ICCA samples. The model effectively stratified patients into high- and low-risk groups, with high-risk patients showing significantly worse survival. The GPSICCA score was positively correlated with stromal and immune scores, suggesting its predictive capability is related to TME involvement in ICCA. The GPSICCA model is a strong predictor of survival in ICCA patients and could help guide treatment strategies and identify potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.